A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

被引：0

作者：

Fowler, Nathan ^{[1
]}

McLaughlin, Peter ^{[1
]}

Hagemeister, Fredrick B. ^{[1
]}

Kwak, Larry ^{[1
]}

Fanale, Michelle ^{[1
]}

Neelapu, Sattva ^{[1
]}

Fayad, Luis ^{[1
]}

Pro, Barbara ^{[1
]}

Sergent, Crystal ^{[1
]}

White, Shana R. S. ^{[1
]}

Samaniego, Felipe ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：683 / 683

页数：1

共 50 条

[21] Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma [J].

S M Ansell ;

H Tang ;

P J Kurtin ;

P A Koenig ;

G S Nowakowski ;

D A Nikcevich ;

G D Nelson ;

Z Yang ;

D M Grote ;

S C Ziesmer ;

P T Silberstein ;

C Erlichman ;

T E Witzig .

Leukemia, 2012, 26 :1046-1052

[22] Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-Cell non-Hodgkin lymphoma [J].

Kahl, Brad ;

Bartlett, Nancy L. ;

Leonard, John P. ;

Ganjoo, Kristen ;

Williams, Michael E. ;

Czuczman, Myron S. ;

Robinson, K. Sue ;

Joyce, Robin ;

van der Jagt, Richard H. ;

Cheson, Bruce D. .

BLOOD, 2007, 110 (11) :406A-407A

[23] Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma [J].

Ansell, S. M. ;

Tang, H. ;

Kurtin, P. J. ;

Koenig, P. A. ;

Nowakowski, G. S. ;

Nikcevich, D. A. ;

Nelson, G. D. ;

Yang, Z. ;

Grote, D. M. ;

Ziesmer, S. C. ;

Silberstein, P. T. ;

Erlichman, C. ;

Witzig, T. E. .

LEUKEMIA, 2012, 26 (05) :1046-1052

[24] INOTUZUMAB OZOGAMICIN IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA REFRACTORY TO RITUXIMAB AND CHEMOTHERAPY OR RADIOIMMUNOTHERAPY [J].

Goy, A. ;

Leach, J. ;

Tsai, M. ;

Foran, J. ;

Forero, A. ;

Wagner-Johnston, N. ;

Ehmann, C. ;

Egyed, M. ;

Ando, K. ;

Hatake, K. ;

Tobinai, K. ;

Feldman, T. ;

Vandendries, E. ;

Volkert, A. ;

Wang, S. L. ;

Ogura, M. .

HAEMATOLOGICA, 2012, 97 :324-324

[25] Could cisplatin as a front-line treatment in childhood non-Hodgkin's lymphoma be a promising therapy? [J].

Papadopoulou, AL ;

Moschovi, M ;

Panagopoulou-Cristaki, M ;

Anagnostou-Keramida, D ;

Van Vliet-Constantinidou, C ;

Botsonis, A ;

Tsangaris, GT ;

Tzortzatou-Stathopoulou, F .

PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1999, 16 (04) :341-346

[26] Phase II study of oblimersen sodium and rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma. [J].

Pro, B ;

Smith, MR ;

Leber, B ;

Younes, A ;

Fayad, L ;

Hagemeister, FB ;

McLaughlin, P ;

Rodriguez, AM ;

Caddick, Y ;

Zwiebel, JA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :587S-587S

[27] Hepatitis c virus infection and B-cell non-Hodgkin's lymphoma. [J].

Grudeva, JG .

BLOOD, 2005, 106 (11) :247B-247B

[28] Rituximab in B-cell disorders other than non-Hodgkin's lymphoma [J].

Bosly, A ;

Keating, MJ ;

Stasi, R ;

Bradstock, K .

ANTI-CANCER DRUGS, 2002, 13 :S25-S33

[29] Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma [J].

Graf, Solomon A. ;

Lynch, Ryan C. ;

Coffey, David G. ;

Shadman, Mazyar ;

Kanan, Sandra ;

Libby, Edward N., III ;

Warren, Edus H. ;

Godwin, Colin ;

Gooley, Ted ;

Fromm, Jonathan R. ;

Gopal, Ajay K. .

BLOOD, 2018, 132

[30] Clinical trials of dendritic cell vaccination for B-cell non-Hodgkin's lymphoma. [J].

Timmerman, JM ;

Davis, TA ;

Hsu, FJ ;

Benike, C ;

Liles, TM ;

Czerwinski, D ;

Taidi, B ;

van Beckhoven, A ;

Fazio, M ;

Engleman, EG ;

Levy, R .

JOURNAL OF LEUKOCYTE BIOLOGY, 1998, :15-15

← 1 2 3 4 5 →